Thor Medical ASA has made the final investment decision for AlphaOne, the company’s first commercial facility for the production of alpha emitters for precision cancer treatment. With an investment of NOK 200 million, production is expected to start in the third quarter of 2026 to meet the growing global demand for radioisotopes.
The facility will be built at Herøya Industrial Park, in the same building as the pilot facilities that began production in the fourth quarter of 2024.
“This investment decision is backed by multi-year sales agreements with leading radiopharmaceutical players that already secure near full capacity utilization at AlphaOne, reliable feedstock suppliers, and is fully funded through the construction and ramp-up of the plant,” says CEO Jasper C. Kurth in Thor Medical, in a press release yesterday.
Ability to facilitate innovation
Thor Medical's investment in AlphaOne strengthens the industrial park's position as a leading industrial hub for high-tech and sustainable production. "This investment contributes to increased activity, creates new jobs, and attracts even more expertise in advanced industry and technology," says Sverre Gotaas, CEO of Herøya Industripark AS.
"The fact that a forward-thinking player like Thor Medical is choosing Herøya as the base for its commercial production confirms the industrial park's attractive infrastructure, access to expertise, and ability to facilitate innovation. We look forward to following their progress and congratulate Thor Medical on their investment decision!"
Text/photo: Tone Brekke tone.brekke@hipark.no
